• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Half of EU Cancer Trials Show Bias, Study Says

Half of EU Cancer Trials Show Bias, Study Says

September 23, 2019
Colin Stoecker

Half of all cancer drugs approved by the European Medicines Agency (EMA) from 2014 to 2016 were the result of trials that exhibited a high risk of bias and even exaggerated treatment effects, a new research study says.

Researchers at seven institutions in the U.S. and UK examined data from 39 studies resulting in EMA approvals following concern that new drug submissions in Europe lack enough scientific evidence to support approval. According to the study, risk of bias was seen in 19 of the oncology drug trials — in 10 trials owing to missing outcome data and seven due to the way outcomes were measured.

The study was tasked with examining the design characteristics, risk of bias and reporting adequacy of trials of oncology drugs approved by EMA in the three-year period. Oncology is the single largest category of drug approval in the EU. More than one-quarter of EMA approvals in 2017 were for cancer drugs.

Randomized control trials (RCT) comprised 76 percent of the study sample. Only seven approvals were supported by two or more RCTs. Researchers found an increasing percentage of cancer drugs are approved based on findings from non-randomized or single-arm trials, which made up 24 percent of the study sample.

Of the RCTs, 23 trials demonstrated deviations from intended interventions due to either lack of blinding or risk of compromised blinding.

Researchers found that trials evaluating overall survival were at lower risk of bias than those that evaluated other endpoints, such as surrogate measures of clinical benefit for cancer patients. However, overall survival, or the length of time from either the date of diagnosis or start of disease treatment to present, was used as a primary endpoint in only 26 percent of trials.

Other trials evaluated indirect measures of clinical benefit, such as disease response, event-free survival or safety endpoints, which are not always a reliable predictor of whether a patient will live longer and have a better quality of life.

Researchers also identified 10 trials with concerns resulting from inappropriate comparators and non-preferred study endpoints.

Findings of bias differed, the study said, between trials relying on information available from scientific literature as opposed to regulatory documents, such as European Public Assessment Reports (EPAR), indicating that the information being communicated by these different sources is being interpreted differently by sponsors and can result in confusion and misconception.

For example, researchers found in the case of one study, that scientific literature was missing some outcomes data, but the related EPAR provided more information about study and treatment discontinuations. Taken together, the two sources provided a more accurate picture of study results.

“Because cancer drugs are responsible for most of the recent increases in pharmaceutical spending,” the study concludes, “the evidence base that supports their market entry warrants close scrutiny.”

Read the full report here: https://bit.ly/2mjr2qT.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing